These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 2143862)
1. Prophylactic use of the new monoclonal antibody BMA 031 in clinical kidney transplantation. Smely S; Weschka M; Hillebrand G; Dendorfer U; Krombach F; Kurrle R; Land W; Hammer C Transplant Proc; 1990 Aug; 22(4):1785-6. PubMed ID: 2143862 [No Abstract] [Full Text] [Related]
2. In situ antigenic modulation of human graft-infiltrating T cells is induced by OKT3 treatment. Caillat-Zucman S; Legendre C; Noel LH; Bach JF; Kreis H; Chatenoud L Transplant Proc; 1990 Aug; 22(4):1782. PubMed ID: 2143860 [No Abstract] [Full Text] [Related]
3. Immunohistological analysis of T lymphocyte subpopulations in needle core biopsies from OKT3-treated renal allograft recipients. Chauhan B; Mohanakumar T; Flye MW Transplantation; 1990 Dec; 50(6):1058-60. PubMed ID: 2147792 [No Abstract] [Full Text] [Related]
4. In vivo-in vitro correlates of human rejection using flow cytometry with two-color fluorescence on peripheral blood mononuclear cells. Gross U; Thomas F; Matthews C; Thomas J; Cunningham P; Ritter T Transplant Proc; 1987 Feb; 19(1 Pt 2):1609-10. PubMed ID: 2978885 [No Abstract] [Full Text] [Related]
5. The effect of major histocompatibility complex matching on renal pathology and OKT4/OKT8 (CD4/CD8) ratio in renal allograft rejection. Smart YC; Nanra RS; Hibberd AD; Burton RC Transplant Proc; 1987 Feb; 19(1 Pt 2):1627-8. PubMed ID: 3152632 [No Abstract] [Full Text] [Related]
6. Natural killer cell subsets and alloresponsiveness in renal allograft recipients. Shabtai M; Waltzer WC; Pullis CK; Raisbeck AP; Malinowski K; Rapaport FT Transplant Proc; 1990 Aug; 22(4):1846-8. PubMed ID: 2143863 [No Abstract] [Full Text] [Related]
7. Prolonged and repeated courses of OKT3 after liver transplantation. Colledan M; Gridelli B; Rossi G; Caccamo L; Gatti S; Bonara P; Fassati LR; Ferla G; Maggi U; Reggiani P Transplant Proc; 1990 Aug; 22(4):1769-71. PubMed ID: 2143859 [No Abstract] [Full Text] [Related]
8. Degree of modulation of cell-surface CD3 by anti-lymphocyte therapies. Henell KR; Bakke A; Kenny TA; Kimball JA; Barry JM; Norman DJ Transplant Proc; 1991 Feb; 23(1 Pt 2):1070-1. PubMed ID: 1824886 [No Abstract] [Full Text] [Related]
9. In vivo immunosuppressive effects of monoclonal antibodies specific for CD3+, CD4+, CD8+, and MHC class II positive cells. Stevens HP; Roche N; Hovius SE; Jonker M Transplant Proc; 1990 Aug; 22(4):1783-4. PubMed ID: 2143861 [No Abstract] [Full Text] [Related]
10. Prophylactic use of anti-CD3 monoclonal antibody WT32 in kidney transplantation. Frenken LA; Hoitsma AJ; Tax WJ; Koene RA Transplant Proc; 1991 Feb; 23(1 Pt 2):1072-3. PubMed ID: 1824887 [No Abstract] [Full Text] [Related]
11. Principal component analysis of blood lymphocyte subsets--an assessment of intersubset relationships. Shabtai M; Shabtai EL; Waltzer WC; Pullis CK; Malinowski K; Rapaport FT Transplantation; 1991 May; 51(5):1135-7. PubMed ID: 1827690 [No Abstract] [Full Text] [Related]
12. Development of a tolerogenic immune balance and elimination of autoreactive B cells--two important effects of antithymocyte globulin treatment. Söderström T; Olausson M; Blohmé I; Enskog A; Mjörnstedt L; Wramner L; Kjellson B; Brynger H Transplant Proc; 1990 Aug; 22(4):1795-7. PubMed ID: 2117810 [No Abstract] [Full Text] [Related]
13. Expression of the IL-2 receptor (p55 and p75) on peripheral blood lymphocytes in renal transplant recipients. Fujiwara T; Sakagami K; Niguma T; Haisa M; Kawamura T; Kusaka S; Matsuoka J; Shiozaki S; Fujiwara T; Onoda T Transplant Proc; 1991 Feb; 23(1 Pt 1):256-9. PubMed ID: 1824979 [No Abstract] [Full Text] [Related]
14. Discordant expression of CD3 and T-cell receptor antigens on lymphocytes from patients treated with OKT3. Gebel HM; Lebeck LL; Jensik SC; Landay AL; Bray RA Transplant Proc; 1989 Feb; 21(1 Pt 2):1745-6. PubMed ID: 2523590 [No Abstract] [Full Text] [Related]
15. Immunological aspects of allogeneic partial hand transplantation in the rhesus monkey. Stevens HP; Hovius SE; Vuzevski VD; van Nierop PW; Gotte M; Roche NA; Jonker M Transplant Proc; 1990 Aug; 22(4):2006-8. PubMed ID: 2143871 [No Abstract] [Full Text] [Related]
17. Acute kidney graft rejection. A morphological and immunohistological study on "zero-hour" and follow-up biopsies with special emphasis on cellular infiltrates and adhesion molecules. Andersen CB; Ladefoged SD; Larsen S APMIS; 1994 Jan; 102(1):23-37. PubMed ID: 7513171 [TBL] [Abstract][Full Text] [Related]
18. Acute cellular rejection during effective early prophylactic OKT3 monoclonal antibody treatment after renal transplantation. Haak HH; Weening JJ; Rischen-Vos J; Daha MR; van Es LA; van der Woude FJ Transplantation; 1989 Aug; 48(2):352-4. PubMed ID: 2526973 [No Abstract] [Full Text] [Related]
19. RIV-9: a mouse IgG3 anti-human CD3 monoclonal antibody with strong antigen modulating and T cell eliminating properties. Vaessen LM; Kreeftenberg JG; Heyse P; Leerling MF; Baumgartner D; Hendriks GF; Jutte NH; Weimer W Transplant Proc; 1989 Feb; 21(1 Pt 1):1026-7. PubMed ID: 2523112 [No Abstract] [Full Text] [Related]